Yon Hui Kim

Dr. Yon Hui Kim


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

4 February 2020 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
JKJin-Hee Kim
Jin-Hee Kim
SPSUNGJIN PARK
SUNGJIN PARK
SLSeung Mook Lim
Seung Mook Lim
HEHyo Jin Eom
Hyo Jin Eom
CBCurt Balch
Curt Balch
YKYon Hui Kim
Yon Hui Kim

22 February 2019 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JKJin-Hee Kim
Jin-Hee Kim
HEHyo Jin Eom
Hyo Jin Eom
GLGyuTae Lim
GyuTae Lim
SPSungjin Park
Sungjin Park
JLJinhyuk Lee
Jinhyuk Lee
JJJin-Hyun Jeong
Jin-Hyun Jeong
Background Gastric cancer (GC) is a highly heterogeneous disease with few “targeted” therapeutic options. Previously, we demonstrated involvement of the transcription factor HNF4α in human GC tumours, and the developmental signal mediator, WNT5A, as a prognostic GC biomarker. One previously developed HNF4α antagonist, BI6015, while not advancing beyond preclinical stages, remains useful for studying GC. Methods Here, we characterised the antineoplastic signalling activity of derivatives of BI6015, including transfer of the nitro group from the para position, relative to a methyl group on its benzene ring, to the ortho- and meta positions. We assessed binding efficacy, through surface plasmon resonance and docking studies, while biologic activity was assessed by antimitogenic efficacy against a panel of GC cell lines, and dysregulated transcriptomes, followed by pathway and subpathway analysis. Results The para derivative of BI6105 was found substantially more growth inhibitory, and effective, in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT. The ortho and meta derivatives, however, failed to downregulate WNT or other embryonic signalling pathways, unable to suppress GC growth. Conclusion Straightforward strategies, employing bioinformatics analyses, to facilitate the effective design and development of “druggable” transcription factor inhibitors, are useful for targeting specific oncogenic signalling pathways, in GC and other cancers.

22 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MBMyeonghun Beak
Myeonghun Beak
SPSUNGJIN PARK
SUNGJIN PARK
JKJin-Hee Kim
Jin-Hee Kim
HEHyo Jin Eom
Hyo Jin Eom
HLHo-Yeon Lee
Ho-Yeon Lee
Seungyoon NamSeungyoon Nam
Seungyoon Nam
Ras homologous A (RHOA), a signal mediator and a GTPase, is known to be associated with the progression of gastric cancer (GC), which is the fourth most common cause of death in the world. Previously, we designed pharmacologically optimized inhibitors against RHOA, including JK-136 and JK-139. Based on this previous work, we performed lead optimization and designed novel RHOA inhibitors for greater anti-GC potency. Two of these compounds, JK-206 and JK-312, could successfully inhibit the viability and migration of GC cell lines. Furthermore, using transcriptomic analysis of GC cells treated with JK-206, we revealed that the inhibition of RHOA might be associated with the inhibition of the mitogenic pathway. Therefore, JK-206 treatment for RHOA inhibition may be a new therapeutic strategy for regulating GC proliferation and migration.

13 September 2021 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
Seungyoon NamSeungyoon Nam
Seungyoon Nam
SLSungyoung Lee
Sungyoung Lee
SPSungjin Park
Sungjin Park
JLJinhyuk Lee
Jinhyuk Lee
APAron Park
Aron Park
Taesung ParkTaesung Park
Taesung Park
Drug repositioning reveals novel indications for existing drugs and in particular, diseases with no available drugs. Diverse computational drug repositioning methods have been proposed by measuring either drug-treated gene expression signatures or the proximity of drug targets and disease proteins found in prior networks. However, these methods do not explain which signaling subparts allow potential drugs to be selected, and do not consider polypharmacology, i.e. multiple targets of a known drug, in specific subparts. Here, to address the limitations, we developed a subpathway-based polypharmacology drug repositioning method, PATHOME-Drug, based on drug-associated transcriptomes. Specifically, this tool locates subparts of signaling cascading related to phenotype changes (e.g. disease status changes), and identifies existing approved drugs such that their multiple targets are enriched in the subparts. We show that our method demonstrated better performance for detecting signaling context and specific drugs/compounds, compared to WebGestalt and clusterProfiler, for both real biological and simulated datasets. We believe that our tool can successfully address the current shortage of targeted therapy agents. The web-service is available at http://statgen.snu.ac.kr/software/pathome. The source codes and data are available at https://github.com/labnams/pathome-drug. Supplementary data are available at Bioinformatics online.